Item 8.01 Other Events

On August 12, 2020, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the peer-reviewed journal, PLOS ONE, has published a paper that further elucidates antiviral activities of CRV431, the Company's lead drug candidate, which is currently in a Phase 2a clinical trial for NASH fibrosis. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits

  99.1         Hepion Pharmaceuticals, Inc. Press Release dated August 12, 2020

© Edgar Online, source Glimpses